Biomarkers market projected to reach $112 billion by 2031

The surge in market value reflects a broader shift toward personalized medicine and the integration of AI-enabled analysis in clinical research. Consumables currently dominate the sector, accounting for 73.4% of offerings in 2025, while safety biomarkers represent the largest share by type. Genomics remains the primary research area, fueled by decreasing sequencing costs and the ability to link genetic data directly to patient drug responses.

Technological innovation is serving as the primary catalyst for this growth. Next-generation sequencing is emerging as the fastest-growing technology, providing the scale necessary for comprehensive genomic profiling in oncology and rare disease research. While North America currently maintains the largest regional market share due to its dense concentration of biopharmaceutical firms and robust clinical trial infrastructure, the Asia Pacific region is expanding more rapidly, posting a 12.4% growth rate.

Industry leaders such as F. Hoffmann-La Roche, Thermo Fisher Scientific, and Abbott continue to refine their portfolios to meet the rising demand for liquid biopsy and minimally invasive testing. As researchers leverage multi-omic panels and high-throughput automation, the industry is increasingly focused on developing actionable insights that support value-based care and more precise clinical trial stratification.